-- Net Vancocin sales are expected to be $235 to $245 million;
-- Research and development (R&D) and selling, general and administrative
(SG&A) expenses, excluding the impact of SFAS 123R, are expected to be
$115 to $125 million.
-- The SFAS 123R impact to the above expenses will be approximately 9
million. Including the impact of SFAS 123R, the research and
development (R&D) and sales, general and administrative (SG&A) expenses
are expected to be between $124 and $134 million.
This press release includes non-GAAP financial information as the Company's projected research and development and marketing, general and administrative expenses has been presented excluding the effect of stock option expense resulting from the application of SFAS 123R. The Company believes that presenting its research and development (R&D) expense and sales, general and administrative (SG&A) expense in this release both with and without the impact of share-based compensation will allow investors to better understand the Company's financial results and how such results compare with the Company's prior results and current guidance.
Conference Call and Webcast
ViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on October 29, 2008 at 9:00 a.m. Eastern Time. To participate in the conference call, please dial 877-366-0713 (domestic) and 302-607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.
Alternatively, the live webcast of the conference call can be accessed
via ViroPharma's website at http://www.viropharma.com. Windows Media or
Real Player will be needed to access the webcast. An a
|SOURCE ViroPharma Incorporated|
Copyright©2008 PR Newswire.
All rights reserved